US equities |
NVDA $236.96 ▲+1.28% MU $1,056.79 ▼-1.68% SPCX $163.84 ▲+3.07% MSFT $529.38 ▲+2.29% TSLA $373.45 ▲+0.77% INTC $117.18 ▼-1.80% SNDK $1,725.72 ▲+0.33% AMD $629.98 ▼-0.62%
FinancialContent

Novo Nordisk A/S Common Stock (NY:NVO)

36.99 -0.33 (-0.88%)
Delayed Quote Updated: 9:49 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
News headline image
Why Novo Nordisk Stock Topped the Market on Thursday ↗
A proposed new federal law could provide some competitive guardrails for the company's most important product. 
Via The Motley Fool
News headline image
Navigating Nuance: Tech Innovation, Healthcare Revival, and Energy's Evolving Landscape Shape Late 2025 Markets
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Novo Nordisk (NVO) Q3 2025 Earnings Transcript ↗
Novo Nordisk (NVO) Q3 2025 Earnings Transcript 
Via The Motley Fool
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗
Via Stocktwits
Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗
Via Stocktwits
News headline image
Eli Lilly's Retatrutide Soars: Unprecedented Trial Results Propel Pharma Giant, Ignite Obesity Market
Eli Lilly and Company (NYSE: LLY) has once again sent ripples through the pharmaceutical world with the announcement of groundbreaking Phase 3 trial results for its investigational obesity drug,... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Golden Cross Alert: 3 Stocks With Major Upside Potential ↗
Via MarketBeat
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Absurdly Cheap Stocks That Look Like Steals Right Now ↗
These stocks are down more than 20% this year, but they possess lots of upside potential over the long term. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Why Wave Life Sciences Stock Crushed it Again Today ↗
There's nothing like a nearly 150% price gain to garner the attention of investors and analysts. 
Via The Motley Fool
News headline image
Prediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026. ↗
A new revenue driver may be just ahead. 
Via The Motley Fool
News headline image
5 High Short-Interest Stocks to Buy Before Q1 2026 ↗
Via MarketBeat
News headline image
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday ↗
We have an emerging new entrant in the increasingly crowded weight loss drug space. 
Via The Motley Fool
News headline image
Novo Nordisk (NYSE:NVO) Embodies Quality Investing Principles ↗
Novo Nordisk exemplifies quality investing with exceptional profitability, strong growth, and a durable competitive advantage in healthcare. 
Via Chartmill
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗
The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable. 
Via The Motley Fool
News headline image
Trump Administration Eases Investment Deadlines For Large Pharma Companies: Report ↗
The report added that at least one of these companies expects to fulfill the multi-billion-dollar investment pledge in full by Jan. 1, 2029. 
Via Stocktwits
Topics Artificial Intelligence Government Workforce
News headline image
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year ↗
A key catalyst may be right around the corner. 
Via The Motley Fool
News headline image
Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? ↗
There is more to this news than meets the eye. 
Via The Motley Fool
Topics Economy Government
News headline image
Novo Nordisk Defends Semaglutide Alzheimer’s Trials After Studies Miss Goals ↗
A Novo Nordisk executive outlined the scientific rationale behind testing Semaglutide in Alzheimer’s disease at a meeting on Tuesday. 
Via Stocktwits
News headline image
The Shifting Tides: How Retail and Institutional Forces Reshape Market Dynamics
As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. 
Via Stocktwits
Topics Intellectual Property
News headline image
Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy ↗
Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect. 
Via Stocktwits
Topics Economy Government
News headline image
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. ↗
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity? 
Via The Motley Fool
News headline image
This 7% Yielder Could Be a Top AI Play ↗
One drug developer could be on the cusp of AI-powered glory. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Why Novo Nordisk Stock Just Hit a 4-Year Low ↗
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company. 
Via The Motley Fool
News headline image
Novo Nordisk A/S (NYSE:NVO) Offers a Strong Dividend and Sound Fundamentals ↗
Novo Nordisk (NVO) is a top dividend stock with a 3.71% yield, strong earnings, and a history of reliable dividend growth, offering dependable income. 
Via Chartmill
News headline image
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results ↗
Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. 
Via The Motley Fool
News headline image
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >